College of Pharmacy, Key Laboratory of New Drug Research and Development of Liaoning Province, Liaoning University, Shenyang 110036, China.
Key Laboratory of Structure-Based Drug Design and Discovery (Shenyang Pharmaceutical University), Ministry of Education, 103 Wenhua Road, Shenhe District, Shenyang 110016, China.
Anticancer Agents Med Chem. 2020;20(5):559-570. doi: 10.2174/1871520620666200101143307.
The Hepatocyte Growth Factor Receptor (HGFR) c-Met is over-expressed and/or mutated in various human tumor types. Dysregulation of c-Met/HGF signaling pathway affects cell proliferation, survival and motility, leading to tumor growth, angiogenesis, and metastasis. Therefore, c-Met has become an attractive target for cancer therapy.
This study is aimed to evaluate a new series of 4-phenoxypyridine derivatives containing semicarbazones moiety for its cytotoxicity.
A series of novel 4-phenoxypyridines containing semicarbazone moieties were synthesized and evaluated for their in vitro cytotoxic activities against MKN45 and A549 cancer cell lines and some selected compounds were further examined for their inhibitory activity against c-Met kinase. In order to evaluate the mechanism of cytotoxic activity of compound 24, cell cycle analysis, Annexin V/PI staining assay, AO/EB assay, wound-healing assay and docking analysis with c-Met were performed.
The results indicated that most of the compounds showed moderate to good antitumor activity. The compound 28 showed well cytotoxic activity against MKN45 and A549 cell lines with IC50 values of 0.25μM and 0.67μM, respectively. Compound 24 showed good activity on c-Met and its IC50 value was 0.093μM.
Their preliminary Structure-Activity Relationships (SARs) studies indicated that electronwithdrawing groups on the terminal phenyl rings are beneficial for improving the antitumor activity. Treatments of MKN45 cells with compound 24 resulted in cell cycle arrest in G2/M phase and induced apoptosis in a dose-dependent manner. In addition, AO/EB assays indicated 24 induced dose-dependent apoptosis of A549 and MKN45 cells. Wound-healing assay results indicated that compound 24 strongly inhibited A549 cell motility.
肝细胞生长因子受体 (HGFR) c-Met 在各种人类肿瘤类型中过表达和/或突变。c-Met/HGF 信号通路的失调会影响细胞增殖、存活和迁移,导致肿瘤生长、血管生成和转移。因此,c-Met 已成为癌症治疗的一个有吸引力的靶点。
本研究旨在评估一系列含有半缩醛肟基的新型 4-苯氧基吡啶衍生物的细胞毒性。
合成了一系列含有半缩醛肟基的新型 4-苯氧基吡啶衍生物,并对其在体外对 MKN45 和 A549 癌细胞系的细胞毒性进行了评价,部分选定的化合物还进一步检测了对 c-Met 激酶的抑制活性。为了评估化合物 24 的细胞毒性作用机制,进行了细胞周期分析、Annexin V/PI 染色分析、AO/EB 分析、划痕愈合试验和与 c-Met 的对接分析。
结果表明,大多数化合物表现出中等至良好的抗肿瘤活性。化合物 28 对 MKN45 和 A549 细胞系表现出良好的细胞毒性活性,IC50 值分别为 0.25μM 和 0.67μM。化合物 24 对 c-Met 具有良好的活性,其 IC50 值为 0.093μM。
它们的初步构效关系 (SAR) 研究表明,末端苯环上的吸电子基团有利于提高抗肿瘤活性。用化合物 24 处理 MKN45 细胞可导致细胞周期停滞在 G2/M 期,并呈剂量依赖性诱导细胞凋亡。此外,AO/EB 分析表明,24 诱导 A549 和 MKN45 细胞呈剂量依赖性凋亡。划痕愈合试验结果表明,化合物 24 强烈抑制 A549 细胞的迁移。